4-diethylaminobutan-3-one | 90226-41-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-diethylaminobutan-3-one
• 英文别名: 1-Diethylamino-butanon-(2)；1-(Diethylamino)butan-2-one
• CAS: 90226-41-8
• 化学式: C₈H₁₇NO
• 分子量: 143.229
• InChiKey: WHYIFPBPPQRYSC-UHFFFAOYSA-N

物化性质

• 沸点：
  33 °C(Press: 0.15 Torr)
• 密度：
  0.868±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-diethylaminobutan-3-one 生成 2-Methyl-3-(diethylamino-methyl)-penten-(2)-ol-(1)
  参考文献：
  名称：

  Tiollais,R. et al., Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques, 1968, vol. 267, p. 1509 - 1511

  摘要：

  DOI：
• 作为产物：
  描述：

  丙酰氯 、 N-ethyl-N-((tributylstannyl)methyl)ethanamine 生成 4-diethylaminobutan-3-one
  参考文献：
  名称：

  N,N-dialkylaminomethyltributyltins as precursors of (N,N-dialkylaminomethyl) ketones

  摘要：

  DOI：

  10.1016/s0040-4039(00)84529-3

文献信息

• Spiroindoline Modulators of Muscarinic Receptors
  申请人：Makings Lewis R.

  公开号：US20120283243A1

  公开（公告）日：2012-11-08

  The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

  本发明涉及肌动蛋白受体调节剂。本发明还提供包含这种调节剂的组合物，并提供使用这些组合物治疗肌动蛋白受体介导疾病的方法。
• MODULATORS OF MUSCARINIC RECEPTORS
  申请人：Makings Lewis R.

  公开号：US20100311746A1

  公开（公告）日：2010-12-09

  The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

  本发明涉及肌动蛋白受体的调节剂。本发明还提供包含这种调节剂的组合物，并提供使用这些组合物治疗肌动蛋白受体介导疾病的方法。
• Glass ionomer dental cement curable in two stages
  申请人：Kerr Manufacturing Company (a Delaware corporation)

  公开号：EP0329268A2

  公开（公告）日：1989-08-23

  A series of dual curing dental cements are disclosed which consist of powder and liquid components to be mixed within a preferred powder to liquid range by weight. Mixing is initiated immediately prior to usage following which the mixed material is applied to the tooth surface as required and cured within a few seconds by irradiation with high intensity visible light energy to a tough leathery consistency, thus permitting the bulk placement of other dental restoratives over it without disturbance. The second stage curing, which is chemically initiated, occurs much more slowly between the powder and the liquid and results in a fully set cement which is hard and rigid. These cements are adhesive, both to prepared tooth structure and to composite dental restorative materials bulk placed over them. Thus, they combine the advantages of conventional dental glass ionomer cements with those of a first generation visible light cured cavity liner.

  本发明公开了一系列双重固化牙科水门汀，由粉末和液体成分组成，按重量计，粉末与液体的混合比例为优选范围。在使用前立即开始混合，然后根据需要将混合材料涂抹在牙齿表面，并通过高强度可见光照射在几秒钟内固化成坚韧的皮革状，从而允许在其上大量放置其他牙科修复材料而不受干扰。第二阶段的固化是化学反应，在粉末和液体之间进行，速度要慢得多，最终形成坚硬的完全固化水门汀。 这些水门汀具有粘接性，既能粘接制备好的牙齿结构，也能粘接置于其上的大量复合牙科修复材料。因此，这些水门汀结合了传统牙科玻璃离聚体水门汀和第一代可见光固化空腔衬垫的优点。
• Compositions and methods for the treatment of cancer
  申请人：CELLIX BIO PRIVATE LIMITED

  公开号：US10858349B2

  公开（公告）日：2020-12-08

  The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII and formula VIII and, the methods for the treatment of cancer and infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cancer, neoplasm, infections and skin diseases.

  本发明涉及这些化合物或其药用可接受的多晶型物、溶剂、对映体、立体异构体和水合物。包含有效量的式 I、式 II、式 III、式 IV、式 V、式 VI、式 VII 和式 VIII 化合物的药物组合物以及治疗癌症和传染性疾病的方法可配制成口服、口腔、直肠、局部、透皮、透粘膜、锭剂、喷雾剂、静脉注射、口服溶液、颊粘膜层片剂、肠外给药、糖浆或注射剂。这些成分可用于治疗癌症、肿瘤、感染和皮肤病。
• Normant; Crisan, Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, 1955, vol. 241, p. 1946
  作者：Normant、Crisan

  DOI：——

  日期：——